PDVAC Executive summary 2020: An update on Tuberculosis vaccine development activities

Overview

2020 WHO Product Development for Vaccines Advisory Committee (PDVAC) Virtual Consultation 6: An update on Tuberculosis vaccine development activities: 3 September 2020

This PDVAC session focused on these two approaches specifically, since there are impending questions related to pivotal study design and data/evidence that if collected, could help to inform future policy recommendations. PDVAC also noted that the TB vaccine pipeline is diverse with respect to platforms, and several candidates are in the clinical pipeline.

The intended outcomes of the PDVAC session were:

• Identification of critical activities that would benefit from PDR/PDVAC leadership and engagement, either related to M72/AS01 and BCG revaccination specifically, or enabling TB vaccine development more generally;
• PDVAC recommendations on the draft TB vaccine roadmap, and a decision related to potential co-authorship with WHO;
• Identification of high priority follow up work to the WHO-funded Full Value Assessment of TB Vaccines project